Results 61 to 70 of about 28,270 (206)

Safety and efficacy of low-dose ticagrelor in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention

Platelets, 2022
It remains unclear whether low-dose ticagrelor offers better safety and similar efficacy for Asian patients with acute coronary syndromes (ACS). We aimed to compare the safety and effectiveness of low-dose ticagrelor vs standard-dose ticagrelor in ...
Yue Wang, Beibei Liu, Leilei Chen, Yue Wang, Zhiqiang Wang, Xiaojiang Zhang, Min Suo, Gary S. Mintz, Xiaofan Wu   +8 more
doaj   +1 more source

Population Pharmacokinetics of Ticagrelor during Veno‐Arterial ECMO in Acute Coronary Syndrome: Model‐Informed Dosing Simulations

Clinical Pharmacology &Therapeutics, EarlyView.
Although patients with acute coronary syndrome supported by veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO) have a high risk of thrombosis and bleeding, antiplatelet pharmacology in this setting is not well defined. This prospective observational study investigated the population pharmacokinetics of ticagrelor and its active metabolite AR ...
Soyoung Kang, Kyoung Lok Min, Seungwon Yang, Jongsung Hahn, Dasohm Kim, Byung Hak Jin, Soon Uk Chae, Soo Kyung Bae, Jin Wi, Min Jung Chang   +9 more
wiley   +1 more source

Pleiotropic Effects of Ticagrelor: Influence on CYP4F2 Gene and Protein Expression in HUVEC and HepG2, and Escherichia coli Bacterial Survival

Drug Design, Development and Therapy, 2022
Ugne Meskauskaite,1 Silvija Andruskeviciute,1 Ieva Ciapiene,1 Agne Giedraitiene,2 Vaiva Lesauskaite,1 Vacis Tatarunas1 1Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania; 2Institute of Microbiology and Virology ...
Meskauskaite U, Andruskeviciute S, Ciapiene I, Giedraitiene A, Lesauskaite V, Tatarunas V   +5 more
doaj  

Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75–100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study

Platelets, 2020
Patients treated with ticagrelor and aspirin usually suffer from bleeding events, especially mild bleeding which is one of the main factors reducing patients’ adherence to ticagrelor.
Jiannan Li, Zhaoxue Sheng, Yu Tan, Chen Liu, Peng Zhou, Jinying Zhou, Runzhen Chen, Yi Chen, Li Song, Hanjun Zhao, Hongbing Yan   +10 more
doaj   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

Ticagrelor — a legend of modern cardiology

Российский кардиологический журнал
The article presents the evidence on the basis of which the ticagrelor is used in patients with various forms of coronary artery disease, including both acute and chronic.
S. R. Gilyarevsky
doaj   +1 more source

Biocatalysis as Useful Tool in Asymmetric Synthesis: An Assessment of Recently Granted Patents (2014–2019) [PDF]

, 2019
The broad interdisciplinary nature of biocatalysis fosters innovation, as different technical fields are interconnected and synergized. A way to depict that innovation is by conducting a survey on patent activities.
Alcántara, Andrés R., Domínguez de María, Pablo, Gonzalo Calvo, Gonzalo de   +2 more
core   +3 more sources

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background Ticagrelor is a P2Y12 receptor inhibitor with superior clinical efficacy compared with clopidogrel. However, it is associated with reduced efficacy when combined with a high‐dose aspirin.
Sukhdeep S. Basra, Tracy Y. Wang, DaJuanicia N. Simon, Karen Chiswell, Salim S. Virani, Mahboob Alam, Vijay Nambi, Ali E. Denktas, Anita Deswal, Biykem Bozkurt, Christie M. Ballantyne, Eric D. Peterson, Hani Jneid   +12 more
doaj   +1 more source

Evaluating the impact of a newly established hospitalist medicine procedure service on length of stay and procedural outcomes: A retrospective propensity‐matched analysis

Journal of Hospital Medicine, EarlyView.
Abstract Background Reliance on interventional radiology (IR) has been associated with delays in procedure completion and prolonged hospital length of stay (LOS). Hospitalist medicine procedure services (HMPS) have been proposed as a strategy to mitigate these inefficiencies, though outcomes of newly established programs composed of physicians with ...
Jeremy Gentile, Saria Alazmeh, Kriti Soni, Tarek Alsibai, Felicia Wright, Alicia Stowe, Fergus Peacock   +6 more
wiley   +1 more source